PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and bax expression

BMB Reports

Volumn 45, Issue 9, 2012, Pages 532-537

  Kim, Duk Soo ^b   Sohn, Eun Jeong ^a   Kim, Dae Won ^a   Kim, Young Nam ^a   Eom, Seon Ae ^a   Yoon, Ga Hyeon ^a   Cho, Sung Woo ^c   Lee, Sang Hyun ^a   Hwang, Hyun Sook ^a   Cho, Yoon Shin ^a   Park, Jinseu ^a   Eum, Won Sik ^a   Choi, Soo Young ^a  

^a Hallym University   (South Korea)

^b Soonchunhyang University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Cell viability; Parkinson's disease; PEP 1 p18; Protein therapy; Protein transduction

Indexed keywords

DRUG DERIVATIVE; MERCAPTAMINE; PEP 1 PEPTIDE; PEP-1 PEPTIDE; PEPTIDE; PROTEIN BAX;

ANIMAL; APOPTOSIS; ARTICLE; CELL LINE; CYTOLOGY; DISEASE MODEL; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; GENE VECTOR; GENETICS; HUMAN; INTOXICATION; METABOLISM; MOUSE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; CYSTEAMINE; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DOPAMINERGIC NEURONS; GENETIC VECTORS; HUMANS; MICE; MPTP POISONING; OXIDATIVE STRESS; PARKINSON DISEASE; PEPTIDES;

EID: 84871261338     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2012.45.9.083     Document Type: Article

References (30)

1. Dawson, T. M. and Dawson, V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
2. Eriksen, J. L., Wszolek, Z. and Petrucelli, L. (2005) Molecular pathogenesis of Parkinson disease. Arch. Neurol. 62, 353-357.
3. Morales-Garcia, J. A., Redondo, M., Alonso-Gil, S., Gil, C., Perex, C., Martinez, A., Santos, A. and Perez-Castillo, A. (2011) Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS ONE 6, e17240.
4. Dauer, W. and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
5. Warner, T. T. and Schapira, A. H. (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53, S16-S25.
6. Eriksen, J. L., Przedborski, S. and Petrucelli, L. (2005) Gene dosage and pathogenesis of Parkinson's disease. Trends Mol. Med. 11, 91-96.
7. Tasaki, Y., Omura, T., Yamada, T., Ohkubo, T., Suno, M., Iida, S., Sakaguchi, T., Asari, M., Shimizu, K. and Matsubara, K. (2010) Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. Brain Res. 1344, 25-33.
8. Subbareddy, M., Sudharsana, R. A., Soumya, P., Ted, P., Kazimierz, W., Anne, Z., Mehdi, E., Kamala, D. M., Emilia, W. and Marek, L. (2007) Cell survival, cell death and cell cycle pathway are interconnected: Implications for cancer therapy. Drug Resist. Updates 10, 13-29.
9. Grant, S. and Roberts, J. D. (2003) The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist. Updates 6, 15-26.
10. Schwartz, G. K. and Shah, M. A. (2005) Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23, 9408-9421.
11. Eduardo, T. C., Maria, E. S., Julieta, M. C., Mariela, C. M., Abel, L. C., Pablo, F. S. and Maria, F. O. (2007) INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59, 419-426.
12. Wadia, J. S. and Dowdy, S. F. (2002) Protein transduction technology. Curr. Opin. Biotechnol. 13, 52-56.
13. Morris, M. C., Depollier, J., Mery, J., Heitz, F. and Divita, G. (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19, 1173-1176.
14. Eum, W. S., Kim, D. W., Hwang, I. K., Yoo, K. Y., Kang, T. C., Jang, S. H., Choi, H. S., Choi, S. H., Kim, Y. H., Kim, S. Y., Kwon, H. Y., Kang, J. H., Kwon, O. S., Cho, S. W., Lee, K. S., Park, J., Won, M. H. and Choi, S. Y. (2004) In vivo protein transduction: Biologically active intact PEP-1-superoxide dismutase fusion protein efficiently pro tects against ischemic insult. Free Radic. Biol. Med. 37, 1656-1669.
15. Choi, H. S., An, J. J., Kim, S. Y., Lee, S. H., Kim, D. W., Yoo, K. Y., Won, M. H., Kang, T. C., Kwon, H. J., Kang, J. H., Cho, S. W., Kwon, O. S., Park, J., Eum, W. S. and Choi, S. Y. (2006) PEP-1-SOD fusion protein efficiently protects against paraquat-induced dopaminergic neuron damage in a Parkinson disease mouse model. Free Radic. Biol. Med. 41, 1058-1068.
16. Ahn, E. H., Kim, D. W., Kang, H. W., Shin, M. J., Won, M. H., Kim, J., Kim, D. J., Kwon, O. S., Kang, T. C., Han, K. H., Park, J., Eum, W. S. and Choi, S. Y. (2010) Transduced PEP-1-ribosomal protein S3 (rpS3) ameliorates 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Toxicol. 276, 192-197.
17. An, J. J., Lee, Y. P., Kim, S. Y., Lee, S. H., Lee, M. J., Jeong, M. S., Kim, D. W., Jang, S. H., Yoo, K. Y., Won, M. H., Kang, T. C., Kwon, O. S., Cho, S. W., Lee, K. S., Park, J., Eum, W. S. and Choi, S. Y. (2008) Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J. 275, 1296-1308.
18. Kim, M. J., Kim, D. W., Yoo, K. Y., Sohn, E. J., Jeong, H. J., Kang, H. W., Shin, M. J., Ahn, J. J., Kwon, S. W., Kim, Y. N., Won, M. H., Cho, S. W., Park, J., Eum, W. S. and Choi, S. Y. (2010) Protective effects of transduced PEP-1-Frataxin protein on oxidative stress-induced neuronal cell death. J. Neurol. Sci. 298, 64-69.
19. Lee, S. H., Kim, D. W., Back, S. S., Hwang, H. S., Park, E. Y., Kang, T. C., Kwon, O. S., Park, J. H., Cho, S. W., Han, K. H., Park, J., Eum, W. S. and Choi, S. Y. (2011) Transduced Tat-annexin protein suppresses inflammation-associated gene expression in lipopolysaccharide (LPS)-stimulated Raw 264.7 cells. BMB Rep. 44, 484-489.
20. Shin, M. J., Lee, Y. P., Kim, D. W., An, J. J., Jang, S. H., Cho, S. M., Sheen, S. H., Lee, H. R., Kweon, H. Y., Kang, S. W., Lee, K. G., Park, J., Eum, W. S., Cho, Y. J. and Choi, S. Y. (2010) Transduced PEP-1-AMPK inhibits the LPS-induced expression of COX-2 and iNOS in Raw 264.7 cells. BMB Rep. 43, 40-45.
21. Egleton, R. D. and Davis, T. P. (1997) Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18, 1431-1439.
22. Dietz, G. P. (2010) Cell-penetrating peptide technology to delivery chaperones and associated factors in diseases and basic research. Curr. Pharm. Biotechnol. 11, 167-174.
23. Kim, S. Y., Kim, M. Y., Mo, J. S., Park, J. W. and Park, H. S. (2007) SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling. Neurosci. Lett. 413, 132-136.
24. Chung, Y. C., Ko, H. W., Bok, E., Park, E. S., Huh, S. H., Nam, J. H. and Jin, B. K. (2010) The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep. 43, 225-232.
25. Brouckaert, G., Kalai, M., Saelens, X. and Vandenabeels, P. (2005) Apoptotic pathways and their regulation. In: Los, M., Gibson. S. B. (eds.), Apoptotic pathway as target for novel therapies in cancer and other diseases. Springer Academic Press, New York, USA.
26. Finkel, E. (2001) The mitochondrian: is it central to apoptosis? Science 292, 624-626.
27. Maddika, S., Mendoza, F. J., Fauff, K., Zamzow, C. R., Paranjothy, T. and Los, M. (2006) Cancer-selective therapy of the further: apoptin and its mechanism of action. Cancer Biol. Ther. 5, 10-19.
28. Deng, X., Gao, F. and May JR, W. S. (2003) Bcl-2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 102, 3179-3185.
29. Araki, T., Mikami, T., Tanji, H., Matsubara, M., Imai, Y., Mizugaki, M. and Itoyama, Y. (2001). Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur. J. Pharm. Sci. 12, 231-238.
30. Bradford, M. A. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.